Ernexa Therapeutics Inc. Line of Credit Facility, Remaining Borrowing Capacity
Ernexa Therapeutics Inc. (ERNA) had Line of Credit Facility, Remaining Borrowing Capacity of $6.50 million as of 2016-12-31, per its 10-K filed 2017-03-09.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity · last filed 2017-03-09
- 2016-12-31: Line of Credit Facility, Remaining Borrowing Capacity $6.50M.
- 2016-09-30: Line of Credit Facility, Remaining Borrowing Capacity $6.50M.
- 2016-06-30: Line of Credit Facility, Remaining Borrowing Capacity $6.50M.
- 2016-03-31: Line of Credit Facility, Remaining Borrowing Capacity $6.50M.
| Period end | Line of Credit Facility, Remaining Borrowing Capacity |
|---|---|
| 2016-12-31 | $6.50M 10-K · filed 2017-03-09 |
| 2016-09-30 | $6.50M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $6.50M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $6.50M 10-Q · filed 2016-05-09 |
| 2013-03-31 | $39.00K 10-Q · filed 2013-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |